Please upgrade your browser.
Dr. Ruth E Langley and colleagues provide an overview of the evidence in favor of aspirin in cancer despite aspirin being neither new nor expensive, in a recent review in the British Journal of Cancer (British Journal of Cancer...
Researchers have identified a novel rare, germline mutation linked to a predisposition for both melanoma and renal cell carcinoma (RCC) that results in a five-fold increased risk of developing melanoma, RCC, or both.
The absolute risk differences for users versus nonusers of nonaspirin NSAIDs were 9.15 per 100,000 person-years in women and 10.92 per 100,000 person-years in men.
Surgical pathology reports vary somewhat regarding the information that they contain; however, each report will document the significant details that affect the management of your diagnosis.
Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes.
CancerNomograms.com is a project of Fox Chase Cancer Center which seeks to be the preeminent source of implementations of the most current and cutting-edge predictive nomograms and other patient health and evaluative models available for a multitude of disease sites.
A report on this medical meeting held annually in downtown Chicago
Ghanaian actress Juliet Ibrahim is making plans to launch her Juliet Ibrahim Foundation (JIF) in December to start an awareness campaign about cancer of the kidney.
With 3.2 million members, Blue Shield appears to be the largest health insurer so far to stop covering Avastin...
RENCAREX® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) of its investigational compound RENCAREX® which is currently undergoing the pivotal Phase III trial ARISER for the adjuvant treatment of patients with non-metastatic clear cell Renal Cell Carcinoma (ccRCC) at high risk of relapse after surgery.
|NeonCRM by Neon One|